Clinical Efficacy Of Percutaneous Neuromuscular Electrical Stimulation Combined With Ningmitai In The Treatment Of Prostate-Pelvic Syndrome

Objective:To explore the clinical efficacy and safety of percutaneous neuromuscular electrical stimulation combined with Ningmitai in the treatment of Prostate-Pelvic Syndrome Methods:From May 2022 to December 2022,90 patients who met the diagnostic criteria for Prostate-Pelvic Syndrome in the urological department of our hospital were randomly divided into three groups: Group A(Ningmitai group),Group B(percutaneous neuromuscular electrical stimulation group),and Group C(percutaneous neuromuscular electrical stimulation combined with Ningmitai group),with 30 patients in each group.Group A patients were treated with oral Ningmitai capsule alone(1.14 g,tid),Group B patients were treated with percutaneous neuromuscular electrical stimulation alone,and Group C patients were treated with percutaneous neuromuscular electrical stimulation combined with Ningmitai.The treatment time of all three groups was 8 weeks,and the general clinical baseline data of all patients were recorded.Before and after treatment,NIH-CPSI scores were performed on all patients,and maximum urinary flow rate(Qmax)was measured.By comparing the changes in NIH-CPSI scores and maximum urinary flow rate of patients in each group before and after intervention,the clinical efficacy of different treatment schemes was analyzed,and the occurrence of adverse reactions in each group was compared.Results:There were no significant differences in general clinical data such as age,height,weight,body mass index(BMI),maximum urinary flow rate(Qmax),and total NIH-CPSI score among the three groups before intervention(P>0.05).Compared with before intervention,pain symptom score,lower urinary tract symptom score,quality of life score and NIH-CPSI total score in group A,B and C were significantly lower after intervention(P<0.05);The maximum urine flow rate of the three groups of patients after intervention was significantly increased,with a statistically significant difference(P<0.05)In the inter-group comparison of the maximum urine flow rate after intervention in the three groups,the maximum urine flow rate after intervention in group C was higher than that in group A and group B,the difference was statistically significant(P<0.05);However,there was no statistical difference between group A and group B in the maximum urine flow rate after intervention(P>0.05);In the inter-group comparison of the total NIH-CPSI score after the intervention of the three groups,the total NIH-CPSI score of group C was significantly lower than that of group A and group B(P<0.05).In the inter-group comparison of group A and B,B and C,A and C,the total NIH-CPSI score after the intervention was statistically different(P<0.05)After intervention,the total effective rate of group A was 73.33%(22/30),group B was 80%(24/30),and group C was 96.67%(29/30).The total effective rate of group C was higher than that of group A and group B,the difference was statistically significant(P<0.05).There was no significant difference in the comparison of adverse reaction events among the three groups(P>0.05)Conclusion:The use of percutaneous neuromuscular electrical stimulation combined with Ningmitai in the treatment of patients with Prostate-Pelvic Syndrome can synergistically relieve symptoms,significantly reduce the pain symptom score,lower urinary tract symptom score,quality of life score and NIH-CPSI total score.The combination of the two can make the curative effect superimposed,and can improve the maximum urine flow rate of patients,which has important clinical value.No major adverse reactions occurred during the intervention,which is safe and feasible,but the long-term treatment effect still needs to expand the sample for clinical research...